JUL 0 9 2004 8

PTO/SB/21 (02-04) Approved for use through 07/31/2006. OMB 0651-0031

| User the Paperwork Reduction Act of 1995 | i, no persons are requ | IIS Patent and Trade | mark Of | fice; U.S. DEPARTMENT OF COMMERCE pless it displays a valid OMB control number. |
|---|---|---|-----------|--|
| DEMARKOE | | Application Number | | 45,863 |
| TRANSMITTA | \mathbf{L} | Filing Date | Aug | ust 20, 2003 |
| FORM | - - | First Named Inventor | Jona | than C. HELLER et al. |
| (to be used for all correspondence after in | itial filing) | Art Unit | 285 | 5 |
| | | Examiner Name | Una | ssigned |
| Total Number of Pages in This Submission | | Attorney Docket Number | 2919 | 91-707 |
| = | ENCLOSU | RES (Check all that apply) | . <u></u> | |
| Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement | Petition Petition Provisio Power o Change Termina Request CD, Nur | g-related Papers to Convert to a nal Application f Attorney, Revocation of Correspondence Address I Disclaimer for Refund mber of CD(s) 1 | | After Allowance communication to Technology Center (TC) Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Itemized return postcard |
| Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNA | Remarks TURE OF APP | LICANT, ATTORNEY OR AC | GENT | |
| Firm | 39,666, WILSON | SONSINI GOODRICH & ROS | | |
| I hereby certify that this correspondence is being f | acsimile transmitted | F TRANSMISSION/MAILING to the USPTO or deposited with the | United | States Postal Service with sufficient |
| postage as Express mail (Label No. EV333489783 1450 on July 9 2004 | US) in an envelope | addressed to: Commissioner for Pate | ents, P.C |). Box 1450, Alexandria, VA 22313- |
| Typed or printed name Tami O'Bryant | | | | |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Signature



PATENT

Attorney Docket No. 29191-707

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| In re Application |) | PATENT APPLICATION |
|---|----|----------------------|
| Inventor(s): Jonathan C. HELLER et al. |) | |
| Application No.: 10/645,863 |) | Art Unit: 2855 |
| Application No.: 10/043,003 |) | Examiner: Unassigned |
| Filed: August 20, 2003 |) | |
| Title: System of Analyzing Complete Mixtures of Biological and Other Fluids to Identify |) | |
| Biological State Information | _) | |
| Commissioner of Patents | | |
| P.O. Box 1450 | | |

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Sir:

Alexandria, VA 22313-1450

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

| \boxtimes | This s | tatemen | t qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply): |
|-------------|------------------------|--------------------------------|--|
| | | (1) | It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR |
| | | (2) | It is being filed within 3 months of entry of a national stage OR |
| | \boxtimes | (3) | It is being filed before the mail date of the first Office Action on the merits OR |
| | | (4) | It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114. |
| | the fil nation a first | ing date al stage Office | 97(c). If this statement is being filed after the latest of: (1) three months beyond e of a national application; (2) three months beyond the date of entry of the as set forth in §1.491 in an international application; or (3) the mailing date of action on the merits, but before the mailing date of the earlier of a final office §1.113 or a notice of allowance under §1.311, then: |
| | | a certi | fication as specified in §1.97(e) is provided below; or |
| | | a fee with the | of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included ne payment of other papers filed together with this statement. |
| | final o | | 97(d). If this statement is being filed after the mailing date of the earlier of a tion under §1.113 or a notice of allowance under §1.311, but before payment of then: |
| | A. | a certi | fication as specified in §1.97(e) is completed below; and |
| | B. | | tion under 37 C.F.R. §1.97(d) requesting consideration of this statement is tted herewith; and |
| | C. | | of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included ne payment of other papers filed together with this statement. |
| \boxtimes | herewi | ith. Du | ch of the references listed on the attached Forms PTO-1449 are enclosed e to the voluminous nature of the references, each reference is provided in PDF attached CD ROM, clearly titled by publication number or author. |
| \boxtimes | Copies THAT | | erences listed on the attached Form PTO-1449 are enclosed herewith EXCEPT |
| | | | w of the voluminous nature of references, and the likelihood that these nces are available to the Examiner in the file history of the parent application No.), copies are not enclosed herewith. |
| | | | of the foregoing publications are not available to the Examiner, Applicant will yor to supply copies at the Examiner's request. |

| | | accordance with 37 CFR 1.98 (a)(application publication listed on the because this U.S. patent application v | ments and non-patent literature are enclosed in (2). (The U.S. patents and each U.S. patents e attached Form PTO-1449 are not enclosed was filed after June 30, 2003 or this international age under 35 USC §371 after June 30, 2003 (see 37 CFR 1.98 (a)(2)(i). |
|-------------|-------------|---|--|
| | \boxtimes | There are no listed references which a | are not in the English language. |
| | | The relevance of those listed referent follows: | ces which are not in the English language is as |
| | | Attached are copies of search repo | rt(s) from corresponding patent application(s), ission Under MPEP 609 D. |
| | | | shed pending patent applications which may be the attached Submission Under MPEP 609 D. |
| \boxtimes | fees of | | ereby authorized to charge the above-referenced or credit any overpayment associated with this 415 (Docket No. 29191-707). |
| | | | Respectfully submitted, |
| | | | WILSON SONSINI GOODRICH & ROSATI |
| Dated: | | 7/8/04 | By: U.P. Peter Eng, Reg. No. 39,666 |
| 650 Pa | _ | Road 94304-1050 | |

(650) 493-9300 Customer No. 021971

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Application Number 10/645,863

Filing Date August 20, 2003

First Named Inventor Jonathan C. HELLER et al.

Art Unit 2855

Examiner Name Unassigned

(Use as many sheets as necessary)

of

6

Sheet

Attorney Docket Number 29191-707

| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|---|--------------------------------|--|---|
| | | US-5,227,471 | 07-13-1993 | Wright, Jr. | rigures rippear |
| | | US-5,314,996 | 05-24-1994 | Wright, Jr. | |
| | | US-5,639,656 | 06-17-1997 | Wright, Jr. | |
| | | US-6,157,921 | 12-05-2000 | Barnhill | |
| | | US-6,207,370-B1 | 03-27-2001 | Little et al. | |
| | | US-6,306,087-B1 | 10-23-2001 | Barnhill et al. | |
| | | US-6,309,816-B1 | 10-30-2001 | Zhang et al. | |
| | | US-6,363,383-B1 | 03-26-2002 | Kindo et al. | |
| | | US-6,427,141-B1 | 07-30-2002 | Barnhill | |
| | | US-6,558,955-B1 | 05-06-2003 | Kristal et al. | |
| _ | | US-6,658,395-B1 | 12-02-2003 | Barnhill | |
| | | US-6,675,104-B1 | 01-06-2004 | Paulse et al. | |
| | | US-6,714,925-B1 | 03-30-2004 | Barnhill et al. | |
| | | US-2002/0095260-A1 | 07-18-2002 | Huyn | |
| | | US-2002/0138208-A1 | 09-26-2002 | Paulse et al. | |
| | | US-2002/0193950-A1 | 12-19-2002 | Gavin et al. | |
| | | US-2003/0004402-A1 | 01-02-2003 | Hitt et al. | |
| • | | US-2003/0013120-A1 | 01-16-2003 | Patz, Jr. et al. | |
| | - | US-2003/0077611-A1 | 04-24-2003 | Slepnev | |
| | | US-2003/0132114-A1 | 07-17-2003 | Mischak et al. | |
| | | US-2003/0134304-A1 | 07-17-2003 | van der Greef et al. | |
| | | US-2003/0148295-A1 | 08-07-2003 | Wan et al. | |
| | | US-2003/0148922-A1 | 08-07-2003 | Knapp et al. | |
| | | US-2003/0153007-A1 | 08-14-2003 | Chen et al. | |
| | | US-2003/0228639-A1 | 12-11-2003 | Wright et al. | |
| | | US-2004/0005634-A1 | 01-08-2004 | Patz, Jr. et al. | |
| | | US-2004/0018519-A1 | 01-29-2004 | Wright, Jr. | |
| | | US-2004/0029194-A1 | 02-12-2004 | Parish et al. | |
| | | US-2004/0043436-A1 | 03-04-2004 | Vlahou et al. | |
| xaminer | T | | <u></u> | Date | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | Complete if Known | | | | |
|------------------------------|--|------|--------|------------------------|---------------------------|--|--|--|
| Substitute for form 1449/PTO | | | | Application Number | 10/645,863 | | | |
| INFORM | IATION | DISC | LOSURE | Filing Date | August 20, 2003 | | | |
| STATEM | STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | First Named Inventor | Jonathan C. HELLER et al. | | | |
| (Use as | | | | Art Unit | 2855 | | | |
| | | | | Examiner Name | Unassigned | | | |
| Sheet | 2 | of | 6 | Attorney Docket Number | 29191-707 | | | |

| | | FOREIGN | PATENT DO | CUMENTS | | |
|---------------------------------|---|--|--------------------------------|--|---|----|
| Examiner Cite Initials* No.1 | | Foreign Patent Document Country Code ¹ - Number ⁴ - Kind Code ³ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | |
| | | WO-95/25281-A1 | 09-21-1995 | Univ. of Washington | В | + |
| | | WO-01/25791-A2 | 04-12-2001 | Ciphergen Biosystems, Inc. | | †- |
| | | WO-01/36977-A2 | 05-25-2001 | Matritech, Inc. | | + |
| | | WO-01/57263-A1 | 08-09-2001 | Advion Biosciences, Inc. | | + |
| | | WO-01/57518-A2 | 08-09-2001 | Yolbolsum Canada Inc. | | + |
| | | WO-01/71360-A2 | 09-27-2001 | Eastern Virginia Medical School | | T |
| | | WO-02/04957-A2 | 01-17-2002 | Esperion Therapeutics, Inc. | | T |
| | | WO-02/08760-A1 | 01-31-2002 | Biotron Limited | | † |
| | | WO-02/97703-A2 | 12-05-2002 | Emili, Andrew et al. | | T |
| | | WO-02/27329-A2 | 04-04-2002 | Eastern Virginia Medical School | | T |
| | _ | WO-02/46448-A2 | 06-13-2002 | Eastern Virginia Medical School | | T |
| | | WO-03/14302-A2 | 02-20-2003 | MDS Proteomics, Inc. | | Τ |
| | | WO-03/31031-A1 | 04-14-2003 | Ciphergen Biosystems, Inc. et al. | | T |
| _ | | WO-03/38055-A2 | 05-08-2003 | MDS Proteomics, Inc. | | |
| | | WO-03/42774-A2 | 05-22-2003 | Caprion Pharmaceuticals, Inc. | | |
| | | WO-03/72710-A2 | 09-04-2003 | Eastern Virginia Medical School | | |
| | | WO-03/83442-A2 | 10-09-2003 | Perlegen Sciences, Inc. | | T |
| | | WO-03/91695-A2 | 11-06-2003 | Johns Hopkins Univ. | | T |
| | | WO-03/97799-A2 | 11-27-2003 | Eastern Virginia Medical School | | T |
| Examiner signature | | | | Date Considered | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached

Approved for use through 07/31/2006. OMB 06\$1-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/645,863 INFORMATION DISCLOSURE Filing Date August 20, 2003 STATEMENT BY APPLICANT First Named Inventor Jonathan C. HELLER et al. (Use as many sheets as necessary) Art Unit 2855 **Examiner Name** Unassigned Attorney Docket Number 29191-707 Sheet of NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Examiner Cite T2 Initials* No.1 publisher, city and/or country where published. ADKINS, Joshua N., et al., "Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry". The American Society for Biochemistry and Molecular Biology, Inc., MCP Paper (November 15, 2002) ANDERSON, Leigh, et al., "A comparison of selected mRNA and protein abundances in human liver". Electrophoresis (1997), 18:533-537. ANDERSON, N. Leigh, et al., "The Human Plasma Proteome". Molecular & Cellular Proteomics (2002), 1:845-867. BANEZ, Lionel L., et al., "Diagnostic potential of serum proteomic patterns in prostate cancer". The Journal of Urology (2003) 170:442-446. BILLINGSLEY, Janice, "Research offers hope in fight against ovarian cancer". Health & Science (Feb 8, 2002) 3 pages. CAO, Ping et al., "Analysis of peptides, proteins, protein digests, and whole human blood by capillary electrophoresis/electrospray ionization-mass spectrometry using an in-capillary electrode sheathless interface". J Am Soc Mass Spectrometry (1998), 9:1081-1088. CAZARES, L. H., et al., "Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectromety". Clinical Cancer Research (August 2002) 8:2541-2552. CBS News, "Setback for a silient killer". CBS News.com (April 2, 2002), 2 pages. CRISP - Computer retrieval of information on scientific projects [abstract], <http://commons.clt.nlh.gov/crisp3/CRISP_LIB.getdoc?textkey=6388327&p_grant_num=5R01 HG002033-03&p query=&ticket=...>>. Downloaded May 9, 2002, 2 pages. DIAMANDIS, Eleftherios P., "Point proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?". Clinical Chemistry (2003) 49(8)1272-1278. EDITORIAL, "Proteomic diagnostics tested". Nature (June 3, 2004), 429(3)487. ETZIONI, Ruth, et al., "Combining biomarkers to detect disease with application to prostate cancer". Biostatistics (2003), 4(4)523-538. ETZIONI, Ruth, et al., "The case for early detection". Nature Reviews/Cancer (April 2003), 3:1-GERACIMOS, A., "Outwitting Ovarian Cancer". Correlogic Systems, Inc., Press Release dated April 16, 2002, 4 pages. Examiner Date Considered

2830323_1.DOC Attorney Docket No. 29191-707



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/645,863 Filing Date INFORMATION DISCLOSURE August 20, 2003 STATEMENT BY APPLICANT First Named Inventor Jonathan C. HELLER et al. (Use as many sheets as necessary) Art Unit 2855 **Examiner Name** Unassigned Attorney Docket Number 29191-707 of Sheet NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Examiner Cite Initials* publisher, city and/or country where published. T^2 GYGI, Steven P., "Correlation between protein and mRNA abundance in yeast". Molecular and Cellular Biology (March 1999) 1720-1730. HARAN, Christine, "The promise of proteins - Do these tricky molecules hold the answers to cancer?". (October 2---) 43-46. HARRISON, Harold H., et al., "Multiple serum protein abnormalities in carbohydrate-deficient glycoprotein syndrome: pathognomomic finding of two-dimensional electrophoresis?". Clinical Chemistry (1992), 38:1390-1392. HENRY, Celia, "Diagnosing ovarian cancer - Proteomics shows promise of early detection of deadly disease". Science (Feb 18, 2003) 18. HILARIO, Melanie, et al., "Machine learning approaches to lung cancer prediction from mass spectra". Protoemics (2003) 3:1716-1719. HOLLON, Tom "Software Zeroes in on ovarian cancer". The Scientist (April 15, 2002) 16(8):16. JOHANNES, Laura, "Tiny protein may lead to better screen test for prostate cancer". Dow Jones (Nov. 4, 2003), 1-2. LEHRER, S., et al., "Putative protein markers in the sera of men with prostatic neoplasms". BJU International (2003) 92:223-225. LEVINE, Peter, "Correlogic's ovarian cancer test nears market introduction". Diagnostic Testing and Technology Report (July 2003) 1:5-7. LIOTTA, Lance A. et al., "Written in blood", Nature (10/30/2003), 425:905. MARKEY, Mia K., et al. "Decision tree classification of proteins identified by mass spectrometry of blood serum samples from people with and without lung cancer". Proteomics (2003) 3:1678-MARSHALL, John, et al., "Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infraction". Journal of Proteome Research (January 20, 2003) 12 MIAN, Shahid, et al., "A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in vitro conditions". Proteomics (2003) 3:1725-1737. MILLER, Jeremy C., et al., "Antibody microarray profiling of human prostate cancer sera: Antibody screening and identification of potential biomarkers". Proteomics (2003) 3:56-63. Examiner Date Considered signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

2830323 1.DOC

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

| | | | Complete if Known | | | | | | | |
|------------------------|--|--------------------|--|---|-------------------------------------|---|----|--|--|--|
| Substitu | ite for f | orm 1449/P | Ю | Application Number | r | 10/645,863 | | | | |
| INFORMATION DISCLOSURE | | Filing Date | | August 20, 2003 | | | | | | |
| STATEMENT BY APPLICANT | | | First Named Invento | or | Jonathan C. HELLER et al. | | | | | |
| (1 | Use as m | any sheets as | necessary) | Art Unit | | 2855 | | | | |
| | | | | Examiner Name | | Unassigned | | | | |
| Sheet | | 5 o | f 6 | Attorney Docket Nu | mber | 29191-707 | | | | |
| | | | NON PATE | NT LITERATURE I | OOCUMENT | S | | | | |
| | | | | | | when appropriate), title of the | | | | |
| Examiner Initials* | Cite No. item (book, magazine, journal, serial, symposium, catalog, etc.), date, publisher, city and/or country where publisher. | | | | | | T² | | | |
| muais | NU. | NEVILI | | | | used to identify disease state | | | | |
| | | | | ". Proteomics (2003) 3: | | , | | | | |
| | | | | Discriminant models for | high-throughpu | t proteomics mass | | | | |
| | | spectron | neter data". Proteomi | cs (2003) 3:1699-1703. | | | | | | |
| | | | | d decision tree analysis | | | | | | |
| | | | desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients". Clinical Chemistry (2002), 48(10):1835-1843. | | | | | | | |
| | | | | | | Science (Feb 8, 2002) 2 | | | | |
| | | pages. | | | | | | | | |
| | | | | | | el for ovarian cancer using | | | | |
| , | | | | | | MS". ASMS (2003) 2 pages. | | | | |
| | | in quest | SILVA, Chris, "Small company, big partners - Bethesda-based Correlogic Systems enlists allies in quest to bring its concern detection test to market". Washington Business Journal (Aug 30-Sep 5, 2002) 2 pages. | | | | | | | |
| | | SOMOR mass spe | UAI, R. L., et al., "Clectroscopy data: curse | ass prediction and discoes, caveats, cautions". B | very using gene ioinformatics (2 | microarray and proteomics 2003) 19(12):1484-1491. | | | | |
| | | | SORACE, James M., et al., "A data review and re-assessment of ovarian cancer serum proteomic profiling". BMC Bioinformatics (2003) 4(24):1-13. | | | | | | | |
| | | SORLIE subclass | SORLIE, Therese, et al., "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications". PNAS (September 11, 2001), 98(19)10869-10874. | | | | | | | |
| | · | SVEDB (2003) 7 | SVEDBERG, Malin, et al., "Sheathless electrospray from polymer microchips". Anal. Chem. (2003) 75:3934-3940. | | | | | | | |
| , | | and patte | TATAY, Jacob W., "Multiple approaches to data-mining of proteomic data based on statistical and pattern classification methods", Proteomics (2003) 3:1704-1709. | | | | | | | |
| | | TIRUM. | ALAI, Radhakrishna roteome", Molecular | S. et al., "Characterizati & Cellular Proteomics 2 | on of the low m .10 (8/13/2003) | olecular weight human , 1096-1103. | | | | |
| | | TOUCH (2003), 2 | | nosing Ovarian Cancer | by Proteomics". | Genome News Network | | | | |
| Examiner | | | | | Date | | | | | |
| signature | signature | | | | Considered | | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

| | | | Complete if Known | | | | | |
|---|--|------------------|---|---|---|---|--|----------------|
| Substitu | ite for f | orm 1449 | /PTO | | Application Numbe | r | 10/645,863 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Filing Date | | August 20, 2003 | | | |
| | | | First Named Invent | or | Jonathan C. HELLER et al. | | | |
| | | | Art Unit | | 2855 | | | |
| | | | | | Examiner Name | | Unassigned | |
| Sheet 6 of 6 | | | | | Attorney Docket Ni | ımber | 29191-707 | |
| | | | | NON PATE | NT LITERATURE | DOCUMENT | 'S | |
| Examiner Cite Include name of the author (in 0 item (book, magazine, journal, s pub | | | | | serial, symposium, catalo plisher, city and/or count | og, etc.), date, pa ry where publish | ge(s), volume-issue number(s), ed. | T ² |
| | VAN 'T VEER, Laura, et al., "Gene expression profiling predicts clinical outcome of breast cancer". Nature (January 2002) 415:530-536. | | | | | | | |
| | | transii 158(4 | tional):149 | cell carcinoma of 1-1502. | the bladder in urine". A | American Journa | oach for the detection of al of Pathology (April 2001), | |
| | | by ne | VOHRADSKY, J., "Adaptive classification of two-dimensional gel electrophoretic spot patterns by neural networks and cluster analysis". Electrophoresis (1997), 18:2749-2754. | | | | | |
| | | and m 1666. | WANG, Michael Z. et al., "Analysis of human serum proteins by liquid phase isoelectric focusing and matrix-assisted laser desorption/ionization-mass spectrometry", Proteomics (2003), 3:1661-1666. | | | | | |
| | | spectr comp | ometi lex pr | ry: a novel protein otein mixtures". Pr | biochip technology for rostate Cancer and Pros | detection of protatic Diseases (1 | | |
| | | mass | spectr | rometry data", Bio | informatics (2003) 19(1 | 3):1636-1643. | on of ovarian cancer using | |
| | | Using 465. | huma | an growth hormon | e as a model system". J | ournal of Protec | human plasma by LC/MSn: ome Research (2002) 1:459- | |
| | | cance | r". Tl | he Lancet (Aug 9, | 2003), 362:433-439. | | sets in non-small-cell lung | |
| | | high-c | YASUI, Yataka, et al., "A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection". Biostatistics (2003) 4(3):449-463. | | | | | |
| | | (Dece | ZHU, Wei, et al. "Detection of cancer-specific markers amid massive mass spectral data". PNAS (December 9, 2003) 100(25):14666-14761. | | | | | |
| | | ZHU, 3:167 | | | sed disease classification | n using protein | data". Proteomics (2003) | - |
| | | | | · | | | | |
| Examiner Date signature Considered | | | | | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check most beautiful to place a

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

